Astex and Cancer Research UK Collaborate on Clinical Studies of AT9283 in Childhood Cancers
News Feb 12, 2009
Astex Therapeutics Limited has announced that it has entered into a clinical trials agreement with Cancer Research UK to support the further clinical development of the Company’s proprietary drug compound, AT9283, in children and adolescent patients with cancer. AT9283 is a multi-targeted kinase inhibitor of Aurora kinases A and B, JAK2 and Abl kinases.
Under the terms of the agreement a Phase I clinical study of AT9283 in children and adolescent patients with relapsed or refractory solid tumours will be conducted through the Cancer Research UK’s Drug Development Office in collaboration with the Children’s Cancer and Leukaemia Group and a further clinical study of AT9283 in children and adolescent patients with haematological malignancies is also planned.
Astex retains all commercial rights to AT9283 and has already completed one Phase I trial with the compound in adult patients with solid tumours and another Phase I trial using an alternative dosing schedule in patients with solid tumours is ongoing. In addition, AT9283 is showing early signs of clinical activity in a further Phase I/II trial in adult patients with haematological malignancies.
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019